Shire PLC ’s success in defeating hedge fund manager Kyle Bass’ attempt to invalidate its Lialda (mesalamine) patent may bode well for other companies facing inter partes review challenges to their
Novartis AG had reason to cheer in May when an appeals court upheld the validity of two patents covering its Exelon Patch (rivastigmine) for Alzheimer’s disease. But the victory was short-lived. F
In Vitro Diagnostics Acquisitions Cytyc Corp. Vision Systems Ltd. Challenging a bid from Ventana Medical Systems , Cytyc (diagnostics and devices for cancer and women's health) intends to offer $A4